Loading
A phase 3 trial of Avelumab in advanced solid tumours, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.
Avelumab Program Rollover Study is a phase 3 interventional study registered as NCT03815643 by EMD Serono Research & Development Institute, Inc., with 205 participants enrolled, started 2019-03-22 and due to reach its primary completion in 2026-08-21. Interventions recorded: Avelumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merck KGaA (EMD Serono), Avelumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/